[{"id":"2b5e323f-9e4a-4d5e-924a-a741c944cff4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01990209","created_at":"2021-07-13T22:53:46.156Z","updated_at":"2025-02-25T14:56:51.373Z","phase":"Phase 2","brief_title":"Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)","source_id_and_acronym":"NCT01990209","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" PGR","pipe":" | ","alterations":" AR expression","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e orteronel (TAK 700)"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2022-06-30"}]